X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The Company intends to use the proceeds to fund its clinical development programs, including, IMCIVREE (setmelanotide), an MC4R agonist designed to treat hyperphagia and severe obesity, approved by the U.S. Food and Drug Administration for chronic weight management.
Lead Product(s): Setmelanotide Acetate
Therapeutic Area: Genetic Disease Product Name: Imcivree
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Perceptive Advisors LLC
Deal Size: $150.0 million Upfront Cash: Undisclosed
Deal Type: Financing April 01, 2024
Details:
RM-718, an investigational, weekly melanocortin-4 receptor (MC4R)-specific agonist designed to be MC1R-sparing and to potentially avoid hyperpigmentation. It is being evaluated for the treatment of Hypothalamic Obesity.
Lead Product(s): RM-718
Therapeutic Area: Nutrition and Weight Loss Product Name: RM-718
Highest Development Status: Phase IProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 25, 2024
Details:
Imcivree (setmelanotide) is a MC4 receptor agonist indicated for chronic weight management in adult and pediatric patients 6 years of age and older with monogenic or syndromic obesity. It is being evaluated for the treatment of hypothalamic obesity.
Lead Product(s): Setmelanotide Acetate
Therapeutic Area: Nutrition and Weight Loss Product Name: Imcivree
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 22, 2024
Details:
Imcivree (setmelanotide), an MC4R agonist designed to treat hyperphagia and severe obesity, is approved by the FDA for chronic weight management. It is under phase 3 clinical trials for the treatment of hypothalamic obesity.
Lead Product(s): Setmelanotide Acetate
Therapeutic Area: Genetic Disease Product Name: Imcivree
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 04, 2024
Details:
Under the agreement, Rhythm will acquire global rights for LB54640, an investigational oral small molecule MC4R agonist now in Phase 2 clinical trials for patients with acquired hypothalamic obesity and proopiomelanocortin, LEPR, or PCSK1 deficiency obesity.
Lead Product(s): LB54640
Therapeutic Area: Nutrition and Weight Loss Product Name: LB54640
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: LG Chem
Deal Size: $305.0 million Upfront Cash: $100.0 million
Deal Type: Licensing Agreement January 04, 2024
Details:
Imcivree (setmelanotide) is a melanocortin 4 (MC4) receptor agonist. It is the first and only therapy approved in Canada for weight management in adult and pediatric patients 6 years of age and older with obesity due to Bardet-Biedl syndrome (BBS).
Lead Product(s): Setmelanotide Acetate
Therapeutic Area: Genetic Disease Product Name: Imcivree
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 02, 2023
Details:
Imcivree (setmelanotide) is a melanocortin 4 (MC4) receptor agonist, which is investigated for the treatment of treatment for acquired hypothalamic obesity.
Lead Product(s): Setmelanotide Acetate
Therapeutic Area: Nutrition and Weight Loss Product Name: Imcivree
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 18, 2023
Details:
Under the agreement, Genpharm will distribute Imcivree (setmelanotide) to patients in GCC countries for the treatment of hyperphagia and obesity due to Bardet-Biedl syndrome or genetically-confirmed biallelic pro-opiomelanocortin, PCSK1, or leptin receptor deficiency.
Lead Product(s): Setmelanotide Acetate
Therapeutic Area: Nutrition and Weight Loss Product Name: Imcivree
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Genpharm
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 22, 2023
Details:
Imcivree (setmelanotide acetate), recently Canada approved, is a MC4 receptor agonist indicated for chronic weight management in adult and pediatric patients 6 years of age and older with monogenic or syndromic obesity and Control of hunger in bardet-biedl syndrome.
Lead Product(s): Setmelanotide Acetate
Therapeutic Area: Genetic Disease Product Name: Imcivree
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 08, 2023
Details:
Imcivree (setmelanotide acetate) is a melanocortin 4 (MC4) receptor agonist indicated for chronic weight management in adult and pediatric patients 6 years of age and older with monogenic or syndromic obesity and Control of hunger in bardet-biedl syndrome.
Lead Product(s): Setmelanotide Acetate
Therapeutic Area: Genetic Disease Product Name: Imcivree
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 24, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
